Psychemedics Key Executives
This section highlights Psychemedics's key executives, including their titles and compensation details.
Find Contacts at Psychemedics
(Showing 0 of )
Psychemedics Earnings
This section highlights Psychemedics's earnings, including key dates, EPS, earnings reports, and earnings call transcripts.
Next Earnings Date
Last Earnings Results
Earnings Call Transcripts
| Transcript | Quarter | Year | Date | Estimated EPS | Actual EPS |
|---|
Psychemedics Corporation provides testing services for the detection of drugs of abuse through the analysis of hair samples in the United States, Brazil, and internationally. The company offers screening and confirmation by mass spectrometry using industry-accepted practices for cocaine, marijuana, and PCP; amphetamines, including ecstasy, eve, and Adderall; opiates, such as heroin, hydrocodone, hydromorphone, oxycodone, oxymorphone, and codeine; synthetic cannabinoids comprising K2, Spice, and Blaze; benzodiazepines consisting of Xanax, Valium, and Ativan; and nicotine and Fentanyl. Its testing results provide quantitative information that could indicate the approximate amount of drug ingested, as well as historical data that could show a pattern of individual drug use over a longer period-of-time. The company offers its services to employers for applicant and employee testing; and treatment professionals, law enforcement agencies, school administrators, and parents concerned about their children's drug use. Psychemedics Corporation was incorporated in 1986 and is headquartered in Acton, Massachusetts.
$2.67
Stock Price
$15.74M
Market Cap
101
Employees
Acton, MA
Location
Financial Statements
Access annual & quarterly financial statements for Psychemedics, including income statements, balance sheets, and cash flow statements..
Annual Income Statement
| Breakdown | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 | December 31, 2019 |
|---|---|---|---|---|---|
| Revenue | $22.10M | $25.24M | $24.91M | $21.36M | $37.68M |
| Cost of Revenue | $13.69M | $15.95M | $14.64M | $16.47M | $21.23M |
| Gross Profit | $8.41M | $9.29M | $10.26M | $4.89M | $16.44M |
| Gross Profit Ratio | 38.10% | 36.81% | 41.20% | 22.87% | 43.64% |
| Research and Development Expenses | $1.14M | $1.33M | $1.13M | $1.28M | $1.57M |
| General and Administrative Expenses | $7.19M | $5.86M | $6.13M | $6.09M | $7.22M |
| Selling and Marketing Expenses | $3.00M | $3.19M | $2.80M | $3.58M | $4.66M |
| Selling General and Administrative Expenses | $10.19M | $9.05M | $8.93M | $9.67M | $11.88M |
| Other Expenses | $- | $43.00K | $-1.03M | $-140.00K | $58.00K |
| Operating Expenses | $11.33M | $10.37M | $10.05M | $10.95M | $13.45M |
| Cost and Expenses | $25.02M | $26.32M | $24.70M | $27.43M | $34.68M |
| Interest Income | $- | $- | $49.00K | $75.00K | $134.00K |
| Interest Expense | $- | $- | $49.00K | $75.00K | $59.00K |
| Depreciation and Amortization | $2.67M | $3.32M | $3.69M | $3.63M | $2.91M |
| EBITDA | $-251.00K | $2.23M | $3.90M | $-2.44M | $5.91M |
| EBITDA Ratio | -1.14% | -4.29% | 0.84% | -28.40% | 7.96% |
| Operating Income | $-2.92M | $-1.08M | $-3.48M | $-6.07M | $84.00K |
| Operating Income Ratio | -13.22% | -4.29% | -13.97% | -28.40% | 0.22% |
| Total Other Income Expenses Net | $-517.00K | $43.00K | $-1.03M | $-140.00K | $58.00K |
| Income Before Tax | $-3.44M | $-1.04M | $-821.00K | $-6.21M | $3.06M |
| Income Before Tax Ratio | -15.56% | -4.12% | -3.30% | -29.05% | 8.11% |
| Income Tax Expense | $716.00K | $44.00K | $-156.00K | $-2.35M | $1.51M |
| Net Income | $-4.15M | $-1.08M | $-665.00K | $-3.86M | $1.54M |
| Net Income Ratio | -18.80% | -4.29% | -2.67% | -18.07% | 4.09% |
| EPS | $-0.72 | $-0.19 | $-0.12 | $-0.70 | $0.28 |
| EPS Diluted | $-0.72 | $-0.19 | $-0.12 | $-0.70 | $0.28 |
| Weighted Average Shares Outstanding | 5.74M | 5.63M | 5.55M | 5.52M | 5.51M |
| Weighted Average Shares Outstanding Diluted | 5.74M | 5.63M | 5.55M | 5.52M | 5.53M |
| SEC Filing | Source | Source | Source | Source | Source |
| Breakdown | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 | December 31, 2019 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $5.17M | $4.73M | $5.36M | $5.00M | $5.70M | $5.54M | $5.86M | $5.70M | $6.52M | $6.51M | $6.51M | $6.44M | $6.67M | $6.09M | $5.71M | $5.33M | $5.17M | $3.31M | $7.54M | $8.71M |
| Cost of Revenue | $3.14M | $3.18M | $3.23M | $2.94M | $3.61M | $3.48M | $3.65M | $3.46M | $4.18M | $4.24M | $4.07M | $4.25M | $3.60M | $3.65M | $3.15M | $4.06M | $4.04M | $3.57M | $4.81M | $5.23M |
| Gross Profit | $2.04M | $1.55M | $2.12M | $2.06M | $2.09M | $2.06M | $2.21M | $2.25M | $2.33M | $2.27M | $2.44M | $2.19M | $3.08M | $2.44M | $2.57M | $1.28M | $1.13M | $-252.00K | $2.73M | $3.48M |
| Gross Profit Ratio | 39.40% | 32.80% | 39.60% | 41.20% | 36.70% | 37.20% | 37.60% | 39.40% | 35.80% | 34.90% | 37.50% | 33.90% | 46.10% | 40.00% | 45.00% | 23.94% | 21.90% | -7.60% | 36.19% | 39.99% |
| Research and Development Expenses | $172.00K | $189.00K | $209.00K | $285.00K | $275.00K | $286.00K | $298.00K | $323.00K | $328.00K | $357.00K | $318.00K | $313.00K | $244.00K | $293.00K | $280.00K | $299.00K | $305.00K | $345.00K | $331.00K | $354.00K |
| General and Administrative Expenses | $1.88M | $1.59M | $1.79M | $1.90M | $2.20M | $1.44M | $1.65M | $1.50M | $1.59M | $1.45M | $1.33M | $1.99M | $1.33M | $1.28M | $1.53M | $1.37M | $1.34M | $1.85M | $1.53M | $2.53M |
| Selling and Marketing Expenses | $580.00K | $671.00K | $692.00K | $740.00K | $723.00K | $746.00K | $789.00K | $781.00K | $791.00K | $813.00K | $806.00K | $849.00K | $652.00K | $656.00K | $642.00K | $719.00K | $896.00K | $856.00K | $1.11M | $1.20M |
| Selling General and Administrative Expenses | $2.46M | $2.26M | $2.48M | $2.64M | $2.92M | $2.19M | $2.44M | $2.28M | $2.38M | $2.26M | $2.13M | $2.84M | $1.98M | $1.94M | $2.17M | $2.09M | $2.24M | $2.71M | $2.64M | $3.74M |
| Other Expenses | $- | $- | $-3.00K | $-1.00K | $- | $-5.00K | $-5.00K | $-6.00K | $-8.00K | $-9.00K | $66.00K | $-1.09M | $-31.00K | $- | $-14.00K | $-11.00K | $-17.00K | $-39.00K | $-73.00K | $4.00K |
| Operating Expenses | $2.63M | $2.45M | $2.69M | $2.93M | $3.20M | $2.48M | $2.73M | $2.60M | $2.71M | $2.62M | $2.45M | $3.15M | $2.23M | $2.23M | $2.45M | $2.39M | $2.54M | $3.05M | $2.97M | $4.09M |
| Cost and Expenses | $5.77M | $5.63M | $5.92M | $5.87M | $6.81M | $5.95M | $6.39M | $6.06M | $6.89M | $6.86M | $6.52M | $7.40M | $5.82M | $5.88M | $5.60M | $6.44M | $6.58M | $6.62M | $7.78M | $9.32M |
| Interest Income | $- | $- | $- | $- | $- | $5.00K | $- | $32.00K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Interest Expense | $- | $- | $- | $- | $- | $- | $- | $6.00K | $8.00K | $9.00K | $- | $2.17M | $- | $- | $14.00K | $11.00K | $17.00K | $39.00K | $73.00K | $- |
| Depreciation and Amortization | $- | $664.00K | $551.00K | $575.00K | $685.00K | $696.00K | $714.00K | $762.00K | $827.00K | $867.00K | $860.00K | $859.00K | $1.01M | $912.00K | $911.00K | $918.00K | $927.00K | $907.00K | $874.00K | $695.00K |
| EBITDA | $-595.00K | $-235.00K | $-21.00K | $-284.00K | $-422.00K | $279.00K | $186.00K | $406.00K | $452.00K | $525.00K | $850.00K | $-1.20M | $1.86M | $1.12M | $1.03M | $-202.00K | $-482.00K | $-2.44M | $632.00K | $89.00K |
| EBITDA Ratio | -11.50% | -4.95% | -0.30% | -5.86% | -19.41% | 1.50% | -9.01% | -6.24% | 6.94% | -5.25% | 13.06% | -14.99% | 26.26% | 3.40% | 2.05% | -20.79% | -27.23% | -72.39% | -3.21% | -6.95% |
| Operating Income | $-595.00K | $-899.00K | $-567.00K | $-868.00K | $-1.11M | $-417.00K | $-528.00K | $-356.00K | $-375.00K | $-342.00K | $-10.00K | $-965.00K | $850.00K | $207.00K | $117.00K | $-1.11M | $-1.41M | $-3.31M | $-242.00K | $-606.00K |
| Operating Income Ratio | -11.50% | -19.01% | -10.58% | -17.37% | -19.41% | -7.53% | -9.01% | -6.24% | -5.76% | -5.25% | -0.15% | -14.99% | 12.74% | 3.40% | 2.05% | -20.79% | -27.23% | -99.76% | -3.21% | -6.95% |
| Total Other Income Expenses Net | $-11.00K | $1.00K | $-5.00K | $-8.00K | $- | $-505.00K | $-5.00K | $-6.00K | $-8.00K | $-9.00K | $66.00K | $-1.09M | $75.00K | $- | $-14.00K | $-11.00K | $-17.00K | $-39.00K | $-73.00K | $4.00K |
| Income Before Tax | $-606.00K | $-898.00K | $-572.00K | $-876.00K | $-1.11M | $-922.00K | $-533.00K | $-362.00K | $-383.00K | $-351.00K | $56.00K | $-2.06M | $925.00K | $207.00K | $103.00K | $-1.12M | $-1.43M | $-3.35M | $-315.00K | $-602.00K |
| Income Before Tax Ratio | -11.71% | -18.99% | -10.68% | -17.53% | -19.41% | -16.65% | -9.10% | -6.35% | -5.88% | -5.39% | 0.86% | -31.96% | 13.86% | 3.40% | 1.80% | -20.99% | -27.56% | -100.94% | -4.18% | -6.91% |
| Income Tax Expense | $-71.00K | $-71.00K | $116.00K | $69.00K | $992.00K | $-196.00K | $-149.00K | $326.00K | $-286.00K | $-13.00K | $17.00K | $-436.00K | $186.00K | $73.00K | $20.00K | $-577.00K | $-319.00K | $-1.29M | $-156.00K | $-72.00K |
| Net Income | $-535.00K | $-827.00K | $-688.00K | $-945.00K | $-2.10M | $-726.00K | $-384.00K | $-688.00K | $-97.00K | $-338.00K | $39.00K | $-1.62M | $739.00K | $134.00K | $83.00K | $-543.00K | $-1.11M | $-2.05M | $-159.00K | $-530.00K |
| Net Income Ratio | -10.34% | -17.49% | -12.84% | -18.91% | -36.80% | -13.11% | -6.55% | -12.06% | -1.49% | -5.19% | 0.60% | -25.19% | 11.07% | 2.20% | 1.45% | -10.18% | -21.40% | -61.86% | -2.11% | -6.08% |
| EPS | $-0.09 | $-0.14 | $-0.12 | $-0.16 | $-0.36 | $-0.13 | $-0.07 | $-0.12 | $-0.02 | $-0.06 | $0.01 | $-0.29 | $0.13 | $0.02 | $0.01 | $-0.10 | $-0.20 | $-0.37 | $-0.03 | $-0.10 |
| EPS Diluted | $-0.09 | $-0.14 | $-0.12 | $-0.16 | $-0.36 | $-0.13 | $-0.07 | $-0.12 | $-0.02 | $-0.06 | $0.01 | $-0.29 | $0.13 | $0.02 | $0.01 | $-0.10 | $-0.20 | $-0.37 | $-0.03 | $-0.09 |
| Weighted Average Shares Outstanding | 5.89M | 5.82M | 5.81M | 5.81M | 5.75M | 5.71M | 5.68M | 5.73M | 5.64M | 5.61M | 5.59M | 5.59M | 5.54M | 5.54M | 5.54M | 5.53M | 5.53M | 5.52M | 5.30M | 5.52M |
| Weighted Average Shares Outstanding Diluted | 5.89M | 5.82M | 5.81M | 5.81M | 5.75M | 5.71M | 5.68M | 5.73M | 5.64M | 5.61M | 5.65M | 5.59M | 5.63M | 5.63M | 5.64M | 5.54M | 5.53M | 5.52M | 5.52M | 5.89M |
| SEC Filing | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source |
Annual Balance Sheet
| Breakdown | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 | December 31, 2019 |
|---|---|---|---|---|---|
| Cash and Cash Equivalents | $1.96M | $4.75M | $1.99M | $2.83M | $7.28M |
| Short Term Investments | $- | $- | $- | $- | $- |
| Cash and Short Term Investments | $1.96M | $4.75M | $1.99M | $2.83M | $7.28M |
| Net Receivables | $3.71M | $4.08M | $6.79M | $5.85M | $3.78M |
| Inventory | $- | $- | $2 | $- | $- |
| Other Current Assets | $1.14M | $1.14M | $1.50M | $914.00K | $3.09M |
| Total Current Assets | $6.80M | $9.96M | $10.29M | $9.60M | $12.85M |
| Property Plant Equipment Net | $4.89M | $7.25M | $10.24M | $13.52M | $13.74M |
| Goodwill | $- | $- | $- | $- | $- |
| Intangible Assets | $- | $- | $- | $- | $- |
| Goodwill and Intangible Assets | $- | $- | $- | $- | $- |
| Long Term Investments | $- | $- | $- | $- | $- |
| Tax Assets | $- | $691.00K | $160.00K | $2.63M | $1.84M |
| Other Non-Current Assets | $632.00K | $823.00K | $864.00K | $-1.74M | $-901.00K |
| Total Non-Current Assets | $5.52M | $8.77M | $11.27M | $14.40M | $14.68M |
| Other Assets | $- | $- | $- | $- | $- |
| Total Assets | $12.33M | $18.73M | $21.55M | $24.00M | $27.53M |
| Account Payables | $752.00K | $448.00K | $994.00K | $577.00K | $617.00K |
| Short Term Debt | $1.35M | $2.37M | $2.63M | $2.44M | $2.60M |
| Tax Payables | $553.00K | $771.00K | $200.00K | $4.00K | $564.00K |
| Deferred Revenue | $1.01M | $- | $- | $- | $- |
| Other Current Liabilities | $2.05M | $2.13M | $2.00M | $922.00K | $2.05M |
| Total Current Liabilities | $4.71M | $5.72M | $5.83M | $3.94M | $5.83M |
| Long Term Debt | $945.00K | $2.24M | $3.48M | $7.34M | $4.33M |
| Deferred Revenue Non-Current | $- | $-1.19M | $-1.55M | $3.44M | $1.95M |
| Deferred Tax Liabilities Non-Current | $- | $1.49M | $2.15M | $211.00K | $550.00K |
| Other Non-Current Liabilities | $- | $- | $- | $- | $- |
| Total Non-Current Liabilities | $945.00K | $2.24M | $3.48M | $7.55M | $4.88M |
| Other Liabilities | $- | $- | $- | $- | $- |
| Total Liabilities | $5.65M | $7.96M | $9.31M | $11.49M | $10.71M |
| Preferred Stock | $- | $- | $- | $- | $- |
| Common Stock | $32.00K | $32.00K | $31.00K | $31.00K | $31.00K |
| Retained Earnings | $-16.77M | $-11.82M | $-9.55M | $-8.61M | $-3.75M |
| Accumulated Other Comprehensive Income Loss | $-1.63M | $-1.63M | $-1.63M | $-1.63M | $-1.62M |
| Other Total Stockholders Equity | $25.05M | $24.19M | $23.40M | $22.72M | $22.17M |
| Total Stockholders Equity | $6.67M | $10.77M | $12.24M | $12.51M | $16.82M |
| Total Equity | $6.67M | $10.77M | $12.24M | $12.51M | $16.82M |
| Total Liabilities and Stockholders Equity | $12.33M | $18.73M | $21.55M | $24.00M | $27.53M |
| Minority Interest | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $12.33M | $18.73M | $21.55M | $24.00M | $27.53M |
| Total Investments | $- | $- | $- | $- | $- |
| Total Debt | $2.30M | $3.57M | $5.13M | $8.90M | $5.97M |
| Net Debt | $334.00K | $-1.18M | $3.13M | $6.07M | $-1.32M |
Balance Sheet Charts
| Breakdown | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 | December 31, 2019 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and Cash Equivalents | $1.41M | $1.43M | $1.42M | $1.96M | $1.37M | $2.44M | $4.38M | $4.75M | $3.46M | $1.79M | $2.13M | $1.99M | $1.97M | $2.65M | $2.19M | $2.83M | $1.81M | $3.67M | $5.33M | $7.28M |
| Short Term Investments | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Cash and Short Term Investments | $1.41M | $1.43M | $1.42M | $1.96M | $1.37M | $2.44M | $4.38M | $4.75M | $3.46M | $1.79M | $2.13M | $1.99M | $1.97M | $2.65M | $2.19M | $2.83M | $1.81M | $3.67M | $5.33M | $7.28M |
| Net Receivables | $3.33M | $3.07M | $3.90M | $3.71M | $4.98M | $4.01M | $4.07M | $4.08M | $5.76M | $7.39M | $7.37M | $6.79M | $6.95M | $6.51M | $6.54M | $5.85M | $5.72M | $4.59M | $3.56M | $3.78M |
| Inventory | $- | $- | $- | $1 | $1 | $1 | $- | $- | $1 | $1 | $- | $2 | $- | $- | $1 | $- | $1 | $1 | $- | $- |
| Other Current Assets | $1.32M | $1.50M | $870.00K | $1.14M | $1.52M | $1.77M | $1.09M | $1.14M | $1.51M | $1.72M | $1.03M | $1.50M | $2.75M | $2.58M | $1.90M | $914.00K | $1.30M | $1.50M | $3.78M | $3.09M |
| Total Current Assets | $6.05M | $6.01M | $6.19M | $6.80M | $7.87M | $8.23M | $9.54M | $9.96M | $10.72M | $10.90M | $10.53M | $10.29M | $11.67M | $11.74M | $10.63M | $9.60M | $8.83M | $9.75M | $10.78M | $12.85M |
| Property Plant Equipment Net | $3.19M | $3.57M | $4.36M | $4.89M | $5.42M | $6.06M | $6.68M | $7.25M | $7.98M | $8.70M | $9.44M | $10.24M | $11.08M | $12.00M | $12.87M | $13.52M | $14.25M | $15.10M | $13.50M | $13.74M |
| Goodwill | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Intangible Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Goodwill and Intangible Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Long Term Investments | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Tax Assets | $- | $- | $- | $944.00K | $- | $1.28M | $850.00K | $691.00K | $935.00K | $- | $160.00K | $160.00K | $- | $- | $- | $- | $10.00K | $- | $- | $- |
| Other Non-Current Assets | $593.00K | $531.00K | $608.00K | $632.00K | $809.00K | $817.00K | $840.00K | $823.00K | $843.00K | $851.00K | $842.00K | $864.00K | $883.00K | $849.00K | $882.00K | $888.00K | $885.00K | $920.00K | $936.00K | $943.00K |
| Total Non-Current Assets | $3.79M | $4.10M | $4.96M | $6.46M | $6.23M | $8.16M | $8.37M | $8.77M | $9.75M | $9.55M | $10.44M | $11.27M | $11.96M | $12.85M | $13.75M | $14.40M | $15.15M | $16.02M | $14.43M | $14.68M |
| Other Assets | $- | $- | $1 | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Assets | $9.84M | $10.11M | $11.15M | $13.27M | $14.10M | $16.39M | $17.91M | $18.73M | $20.48M | $20.45M | $20.97M | $21.55M | $23.63M | $24.59M | $24.38M | $24.00M | $23.98M | $25.78M | $25.21M | $27.53M |
| Account Payables | $994.00K | $662.00K | $1.13M | $752.00K | $817.00K | $806.00K | $785.00K | $448.00K | $857.00K | $598.00K | $722.00K | $994.00K | $448.00K | $1.10M | $1.11M | $577.00K | $416.00K | $61.00K | $1.23M | $617.00K |
| Short Term Debt | $976.00K | $1.25M | $1.27M | $2.40M | $2.42M | $2.43M | $2.45M | $1.33M | $2.33M | $2.41M | $2.55M | $1.65M | $2.65M | $2.62M | $2.62M | $1.56M | $2.45M | $2.46M | $2.45M | $1.64M |
| Tax Payables | $- | $- | $- | $553.00K | $- | $- | $- | $771.00K | $- | $- | $- | $200.00K | $- | $- | $- | $4.00K | $- | $- | $- | $564.00K |
| Deferred Revenue | $- | $- | $- | $553.00K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Current Liabilities | $1.82M | $1.84M | $1.78M | $1.00M | $2.15M | $2.40M | $2.56M | $3.17M | $2.99M | $2.29M | $2.05M | $2.99M | $2.25M | $925.00K | $604.00K | $1.80M | $473.00K | $759.00K | $1.23M | $3.01M |
| Total Current Liabilities | $3.79M | $3.75M | $4.18M | $4.71M | $5.38M | $5.64M | $5.79M | $5.72M | $6.18M | $5.30M | $5.32M | $5.83M | $5.34M | $4.65M | $4.33M | $3.94M | $3.34M | $3.28M | $4.91M | $5.83M |
| Long Term Debt | $596.00K | $623.00K | $687.00K | $945.00K | $1.28M | $1.62M | $1.95M | $2.24M | $2.58M | $2.91M | $3.18M | $3.48M | $3.97M | $6.59M | $7.03M | $7.34M | $7.70M | $8.09M | $3.99M | $4.33M |
| Deferred Revenue Non-Current | $- | $- | $- | $-945.00K | $-7.00K | $- | $- | $-1.19M | $- | $453.00K | $- | $- | $-290.00K | $-238.00K | $-211.00K | $-211.00K | $- | $-476.00K | $-495.00K | $-550.00K |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $944.00K | $7.00K | $- | $- | $1.49M | $- | $307.00K | $- | $2.15M | $290.00K | $238.00K | $211.00K | $211.00K | $- | $476.00K | $495.00K | $550.00K |
| Other Non-Current Liabilities | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Non-Current Liabilities | $596.00K | $623.00K | $687.00K | $1.89M | $1.29M | $1.62M | $1.95M | $2.24M | $2.58M | $3.22M | $3.18M | $3.48M | $4.26M | $6.82M | $7.24M | $7.55M | $7.70M | $8.57M | $4.49M | $4.88M |
| Other Liabilities | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities | $4.39M | $4.37M | $4.87M | $6.60M | $6.67M | $7.26M | $7.74M | $7.96M | $8.76M | $8.51M | $8.51M | $9.31M | $9.61M | $11.47M | $11.57M | $11.49M | $11.04M | $11.85M | $9.40M | $10.71M |
| Preferred Stock | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Common Stock | $32.00K | $32.00K | $32.00K | $32.00K | $32.00K | $32.00K | $32.00K | $32.00K | $32.00K | $31.00K | $31.00K | $31.00K | $31.00K | $31.00K | $31.00K | $31.00K | $31.00K | $31.00K | $31.00K | $31.00K |
| Retained Earnings | $-18.82M | $-18.29M | $-17.46M | $-16.77M | $-15.83M | $-13.73M | $-12.60M | $-11.82M | $-10.73M | $-10.24M | $-9.51M | $-9.55M | $-7.65M | $-8.39M | $-8.52M | $-8.61M | $-8.06M | $-6.96M | $-4.91M | $-3.75M |
| Accumulated Other Comprehensive Income Loss | $-1.63M | $-1.63M | $-1.63M | $-1.63M | $-1.63M | $-1.63M | $-1.63M | $-1.63M | $-1.63M | $-1.63M | $-1.63M | $-1.63M | $-1.63M | $-1.63M | $-1.63M | $-1.63M | $-1.63M | $-1.63M | $-1.65M | $-1.62M |
| Other Total Stockholders Equity | $25.87M | $25.63M | $25.34M | $25.05M | $24.86M | $24.46M | $24.37M | $24.19M | $24.06M | $23.78M | $23.57M | $23.40M | $23.28M | $23.11M | $22.94M | $22.72M | $22.61M | $22.48M | $22.33M | $22.17M |
| Total Stockholders Equity | $5.45M | $5.74M | $6.28M | $6.67M | $7.43M | $9.13M | $10.17M | $10.77M | $11.72M | $11.94M | $12.46M | $12.24M | $14.03M | $13.12M | $12.81M | $12.51M | $12.94M | $13.92M | $15.81M | $16.82M |
| Total Equity | $5.45M | $5.74M | $6.28M | $6.67M | $7.43M | $9.13M | $10.17M | $10.77M | $11.72M | $11.94M | $12.46M | $12.24M | $14.03M | $13.12M | $12.81M | $12.51M | $12.94M | $13.92M | $15.81M | $16.82M |
| Total Liabilities and Stockholders Equity | $9.84M | $10.11M | $11.15M | $13.27M | $14.10M | $16.39M | $17.91M | $18.73M | $20.48M | $20.45M | $20.97M | $21.55M | $23.63M | $24.59M | $24.38M | $24.00M | $23.98M | $25.78M | $25.21M | $27.53M |
| Minority Interest | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $9.84M | $10.11M | $11.15M | $13.27M | $14.10M | $16.39M | $17.91M | $18.73M | $20.48M | $20.45M | $20.97M | $21.55M | $23.63M | $24.59M | $24.38M | $24.00M | $23.98M | $25.78M | $25.21M | $27.53M |
| Total Investments | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Debt | $1.58M | $1.87M | $1.96M | $2.30M | $2.64M | $2.99M | $3.32M | $3.57M | $3.92M | $4.34M | $4.74M | $5.13M | $5.64M | $8.24M | $8.68M | $8.90M | $9.27M | $9.67M | $5.56M | $5.97M |
| Net Debt | $174.00K | $434.00K | $539.00K | $334.00K | $1.27M | $541.00K | $-1.06M | $-1.18M | $467.00K | $2.56M | $2.61M | $3.13M | $3.68M | $5.59M | $6.49M | $6.07M | $7.46M | $5.99M | $229.00K | $-1.32M |
Annual Cash Flow
| Breakdown | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 | December 31, 2019 |
|---|---|---|---|---|---|
| Net Income | $-4.15M | $-1.08M | $-665.00K | $-3.86M | $1.54M |
| Depreciation and Amortization | $2.67M | $3.32M | $3.69M | $3.63M | $2.91M |
| Deferred Income Tax | $691.00K | $-531.00K | $-371.00K | $-339.00K | $-405.00K |
| Stock Based Compensation | $908.00K | $872.00K | $743.00K | $563.00K | $759.00K |
| Change in Working Capital | $-1.73M | $2.32M | $-802.00K | $-4.17M | $-534.00K |
| Accounts Receivables | $373.00K | $377.00K | $-760.00K | $424.00K | $1.05M |
| Inventory | $- | $- | $- | $- | $- |
| Accounts Payables | $304.00K | $-546.00K | $417.00K | $-281.00K | $-494.00K |
| Other Working Capital | $-2.40M | $2.49M | $-459.00K | $-4.31M | $-1.09M |
| Other Non Cash Items | $131.00K | $5.33M | $-2.18M | $94.00K | $33.00K |
| Net Cash Provided by Operating Activities | $-1.48M | $4.89M | $414.00K | $-4.08M | $4.31M |
| Investments in Property Plant and Equipment | $-157.00K | $-187.00K | $-182.00K | $-991.00K | $-1.73M |
| Acquisitions Net | $- | $- | $- | $140.00K | $- |
| Purchases of Investments | $- | $- | $- | $- | $- |
| Sales Maturities of Investments | $- | $- | $- | $- | $3.81M |
| Other Investing Activities | $-2.00K | $-21.00K | $-38.00K | $-7.00K | $3.75M |
| Net Cash Used for Investing Activities | $-159.00K | $-208.00K | $-220.00K | $-858.00K | $2.08M |
| Debt Repayment | $-294.00K | $-664.00K | $-688.00K | $1.50M | $1.00M |
| Common Stock Issued | $- | $- | $72.00K | $- | $- |
| Common Stock Repurchased | $-54.00K | $-78.00K | $-72.00K | $-9.00K | $-33.00K |
| Dividends Paid | $-799.00K | $-1.19M | $-279.00K | $-993.00K | $-3.97M |
| Other Financing Activities | $-54.00K | $4.00K | $-68.00K | $- | $- |
| Net Cash Used Provided by Financing Activities | $-1.15M | $-1.92M | $-1.03M | $501.00K | $-3.00M |
| Effect of Forex Changes on Cash | $- | $- | $- | $-10.00K | $-170.00K |
| Net Change in Cash | $-2.79M | $2.76M | $-841.00K | $-4.45M | $3.21M |
| Cash at End of Period | $1.96M | $4.75M | $1.99M | $2.83M | $7.28M |
| Cash at Beginning of Period | $4.75M | $1.99M | $2.83M | $7.28M | $4.07M |
| Operating Cash Flow | $-1.48M | $4.89M | $414.00K | $-4.08M | $4.31M |
| Capital Expenditure | $-157.00K | $-187.00K | $-182.00K | $-991.00K | $-1.73M |
| Free Cash Flow | $-1.64M | $4.70M | $232.00K | $-5.07M | $2.58M |
Cash Flow Charts
| Breakdown | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 | December 31, 2019 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $-535.00K | $-827.00K | $-688.00K | $-945.00K | $-2.10M | $-726.00K | $-384.00K | $-688.00K | $-97.00K | $-338.00K | $39.00K | $-1.62M | $739.00K | $134.00K | $83.00K | $-543.00K | $-1.11M | $-2.05M | $-159.00K | $-530.00K |
| Depreciation and Amortization | $453.00K | $664.00K | $551.00K | $575.00K | $685.00K | $696.00K | $714.00K | $762.00K | $827.00K | $867.00K | $860.00K | $859.00K | $1.01M | $912.00K | $911.00K | $918.00K | $927.00K | $907.00K | $874.00K | $695.00K |
| Deferred Income Tax | $- | $- | $- | $-7.00K | $1.29M | $-593.00K | $-159.00K | $244.00K | $-1.24M | $467.00K | $- | $-450.00K | $52.00K | $27.00K | $- | $221.00K | $-486.00K | $-19.00K | $-55.00K | $-267.00K |
| Stock Based Compensation | $240.00K | $287.00K | $297.00K | $187.00K | $401.00K | $143.00K | $177.00K | $178.00K | $277.00K | $238.00K | $179.00K | $179.00K | $178.00K | $169.00K | $217.00K | $114.00K | $126.00K | $160.00K | $163.00K | $250.00K |
| Change in Working Capital | $637.00K | $-4.00K | $-633.00K | $721.00K | $-1.24M | $-479.00K | $-732.00K | $1.40M | $2.57M | $-917.00K | $-733.00K | $1.60M | $-184.00K | $-592.00K | $-1.62M | $430.00K | $-954.00K | $-2.31M | $-1.33M | $802.00K |
| Accounts Receivables | $-269.00K | $822.00K | $-191.00K | $1.27M | $-595.00K | $57.00K | $-319.00K | $1.21M | $-548.00K | $299.00K | $-588.00K | $565.00K | $-710.00K | $49.00K | $-664.00K | $534.00K | $-1.33M | $998.00K | $222.00K | $1.39M |
| Inventory | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Accounts Payables | $332.00K | $-469.00K | $379.00K | $-65.00K | $11.00K | $21.00K | $337.00K | $-409.00K | $259.00K | $-124.00K | $-272.00K | $546.00K | $-652.00K | $-2.00K | $525.00K | $-77.00K | $352.00K | $-1.13M | $570.00K | $-159.00K |
| Other Working Capital | $574.00K | $-357.00K | $-821.00K | $-487.00K | $-652.00K | $-557.00K | $-750.00K | $593.00K | $2.86M | $-1.09M | $127.00K | $487.00K | $1.18M | $-639.00K | $-1.49M | $-27.00K | $24.00K | $-2.19M | $-2.12M | $-430.00K |
| Other Non Cash Items | $-532.00K | $- | $1.21M | $131.00K | $2.73M | $1.46M | $159.00K | $433.00K | $38.00K | $2.12M | $2.74M | $1.20M | $-2.18M | $1.97M | $2.20M | $-1.51M | $1.41M | $-2.48M | $94.00K | $-2.00K |
| Net Cash Provided by Operating Activities | $263.00K | $120.00K | $-473.00K | $662.00K | $-958.00K | $-959.00K | $-225.00K | $1.89M | $2.33M | $317.00K | $345.00K | $565.00K | $-388.00K | $650.00K | $-413.00K | $1.14M | $-1.49M | $-3.32M | $-413.00K | $948.00K |
| Investments in Property Plant and Equipment | $17.00K | $-39.00K | $-8.00K | $5.00K | $-35.00K | $-56.00K | $-41.00K | $-24.00K | $-91.00K | $-29.00K | $-43.00K | $-30.00K | $-68.00K | $-34.00K | $-50.00K | $-111.00K | $-254.00K | $-344.00K | $-466.00K | $-612.00K |
| Acquisitions Net | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Purchases of Investments | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Sales Maturities of Investments | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $3.81M |
| Other Investing Activities | $-15.00K | $66.00K | $13.00K | $30.00K | $-8.00K | $8.00K | $-32.00K | $4.00K | $-7.00K | $-25.00K | $7.00K | $4.00K | $-50.00K | $17.00K | $-9.00K | $167.00K | $17.00K | $-70.00K | $133.00K | $-3.76M |
| Net Cash Used for Investing Activities | $2.00K | $27.00K | $5.00K | $5.00K | $-43.00K | $-48.00K | $-73.00K | $-20.00K | $-98.00K | $-54.00K | $-36.00K | $-26.00K | $-118.00K | $-17.00K | $-59.00K | $56.00K | $-237.00K | $-344.00K | $-333.00K | $-565.00K |
| Debt Repayment | $-85.00K | $-76.00K | $-75.00K | $-74.00K | $-74.00K | $-74.00K | $-72.00K | $-141.00K | $-174.00K | $-175.00K | $-174.00K | $-173.00K | $-172.00K | $-172.00K | $-171.00K | $-171.00K | $-169.00K | $2.01M | $-169.00K | $1.31M |
| Common Stock Issued | $- | $- | $- | $- | $55.00K | $-55.00K | $- | $-4.00K | $4.00K | $- | $- | $-5.00K | $- | $- | $- | $- | $- | $- | $- | $- |
| Common Stock Repurchased | $- | $- | $- | $1.00K | $- | $-55.00K | $- | $-46.00K | $- | $-32.00K | $- | $5.00K | $-5.00K | $- | $- | $-1.00K | $- | $-8.00K | $- | $- |
| Dividends Paid | $- | $- | $- | $-799.00K | $- | $-799.00K | $- | $-399.00K | $-394.00K | $-393.00K | $- | $-279.00K | $- | $- | $- | $-335.00K | $- | $- | $-993.00K | $-992.00K |
| Other Financing Activities | $-209.00K | $-58.00K | $- | $1.00K | $-55.00K | $- | $- | $4.00K | $-4.00K | $-32.00K | $- | $-63.00K | $-5.00K | $- | $- | $- | $- | $- | $- | $- |
| Net Cash Used Provided by Financing Activities | $-294.00K | $-134.00K | $-75.00K | $-73.00K | $-74.00K | $-928.00K | $-72.00K | $-582.00K | $-568.00K | $-600.00K | $-174.00K | $-515.00K | $-177.00K | $-172.00K | $-171.00K | $-172.00K | $-169.00K | $2.00M | $-1.16M | $321.00K |
| Effect of Forex Changes on Cash | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $10.00K | $37.00K | $-3.00K | $-44.00K | $87.00K |
| Net Change in Cash | $-29.00K | $13.00K | $-543.00K | $594.00K | $-1.07M | $-1.94M | $-370.00K | $1.29M | $1.67M | $-337.00K | $135.00K | $24.00K | $-683.00K | $461.00K | $-643.00K | $1.02M | $-1.86M | $-1.66M | $-1.95M | $791.00K |
| Cash at End of Period | $1.41M | $1.43M | $1.42M | $1.96M | $1.37M | $2.44M | $4.38M | $4.75M | $3.46M | $1.79M | $2.13M | $1.99M | $1.97M | $2.65M | $2.19M | $2.83M | $1.81M | $3.67M | $5.33M | $7.28M |
| Cash at Beginning of Period | $1.43M | $1.42M | $1.96M | $1.37M | $2.44M | $4.38M | $4.75M | $3.46M | $1.79M | $2.13M | $1.99M | $1.97M | $2.65M | $2.19M | $2.83M | $1.81M | $3.67M | $5.33M | $7.28M | $6.49M |
| Operating Cash Flow | $263.00K | $120.00K | $-473.00K | $662.00K | $-958.00K | $-959.00K | $-225.00K | $1.89M | $2.33M | $317.00K | $345.00K | $565.00K | $-388.00K | $650.00K | $-413.00K | $1.14M | $-1.49M | $-3.32M | $-413.00K | $948.00K |
| Capital Expenditure | $17.00K | $-39.00K | $-8.00K | $5.00K | $-35.00K | $-56.00K | $-41.00K | $-24.00K | $-91.00K | $-29.00K | $-43.00K | $-30.00K | $-68.00K | $-34.00K | $-50.00K | $-111.00K | $-254.00K | $-344.00K | $-466.00K | $-612.00K |
| Free Cash Flow | $280.00K | $81.00K | $-481.00K | $667.00K | $-993.00K | $-1.01M | $-266.00K | $1.87M | $2.24M | $288.00K | $302.00K | $535.00K | $-456.00K | $616.00K | $-463.00K | $1.03M | $-1.75M | $-3.66M | $-879.00K | $336.00K |
Psychemedics Dividends
Explore Psychemedics's dividend history, including dividend yield, payout ratio, and historical payments.
Dividend Yield
4.70%
Dividend Payout Ratio
-19.23%
Dividend Paid & Capex Coverage Ratio
-1.55x
Psychemedics Dividend History
| Dividend | Adjusted Dividend | Date | Record Date | Payment Date | Declaration Date |
|---|---|---|---|---|---|
| $0.07 | $0.07 | May 24, 2023 | May 25, 2023 | June 08, 2023 | May 09, 2023 |
| $0.07 | $0.07 | March 30, 2023 | March 31, 2023 | April 10, 2023 | March 21, 2023 |
| $0.07 | $0.07 | December 01, 2022 | December 02, 2022 | December 16, 2022 | November 09, 2022 |
| $0.07 | $0.07 | August 23, 2022 | August 24, 2022 | September 09, 2022 | August 09, 2022 |
| $0.07 | $0.07 | May 26, 2022 | May 27, 2022 | June 24, 2022 | May 10, 2022 |
| $0.05 | $0.05 | December 17, 2021 | December 20, 2021 | December 30, 2021 | December 10, 2021 |
| $0.18 | $0.18 | February 20, 2020 | February 21, 2020 | March 03, 2020 | February 11, 2020 |
| $0.18 | $0.18 | November 04, 2019 | November 05, 2019 | November 15, 2019 | October 22, 2019 |
| $0.18 | $0.18 | August 05, 2019 | August 06, 2019 | August 16, 2019 | July 23, 2019 |
| $0.18 | $0.18 | May 06, 2019 | May 07, 2019 | May 17, 2019 | April 23, 2019 |
| $0.18 | $0.18 | March 13, 2019 | March 14, 2019 | March 25, 2019 | March 04, 2019 |
| $0.18 | $0.18 | November 01, 2018 | November 02, 2018 | November 12, 2018 | October 23, 2018 |
| $0.18 | $0.18 | August 06, 2018 | August 07, 2018 | August 17, 2018 | July 24, 2018 |
| $0.18 | $0.18 | May 07, 2018 | May 08, 2018 | May 18, 2018 | April 24, 2018 |
| $0.15 | $0.15 | March 16, 2018 | March 19, 2018 | March 29, 2018 | March 07, 2018 |
| $0.15 | $0.15 | November 03, 2017 | November 06, 2017 | November 17, 2017 | October 24, 2017 |
| $0.15 | $0.15 | August 10, 2017 | August 14, 2017 | August 24, 2017 | August 03, 2017 |
| $0.15 | $0.15 | May 04, 2017 | May 08, 2017 | May 18, 2017 | April 26, 2017 |
| $0.15 | $0.15 | February 14, 2017 | February 16, 2017 | February 27, 2017 | February 06, 2017 |
| $0.15 | $0.15 | November 03, 2016 | November 07, 2016 | November 17, 2016 | October 27, 2016 |
Psychemedics News
Read the latest news about Psychemedics, including recent articles, headlines, and updates.
Psychemedics Corporation Announces Reverse and Forward Stock Split
DALLAS, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Psychemedics Corporation (Nasdaq: PMD) (the “Company”), the world's leading provider of hair testing for drugs of abuse, today announced that, following the approval of the Company's stockholders at its Annual Meeting of Stockholders held on November 25, 2024, the Company's Board of Directors has approved a 1-for-5,000 reverse stock split of its common stock (the “Reverse Stock Split”) followed immediately by a 5,000-for-1 forward stock split of its common stock (the “Forward Stock Split,” and together with the Reverse Stock Split, the “Stock Split”), to be effective at 5:01 p.m. and 5:02 p.m., Eastern Time, respectively, on Tuesday, December 3, 2024. Beginning with the opening of trading on Wednesday, December 4, 2024, the Company's common stock will continue to trade on the Nasdaq Capital Market on a post-Forward Stock Split basis under the existing symbol “PMD”.
Psychemedics Releases First-Ever Education Insights Report: Uncovering Drug Trends in Educational Institutions Through Hair Testing
DALLAS, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ: PMD), a global leader in hair testing for drugs of abuse, is excited to announce the release of its first-ever Education Insights Report.
Psychemedics Corporation's Board of Directors Approves Plan to Terminate Registration of Its Common Stock
DALLAS, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Psychemedics Corporation (Nasdaq:PMD) (“Psychemedics” or the “Company”) today announced that a Transaction Committee (the “Transaction Committee”) of the Board of Directors of the Company (the “Board”) comprised of independent directors has recommended, and the Board has approved, a plan to cease the registration of the Company's common stock under the federal securities laws following the completion of a proposed reverse stock split and to delist its shares of common stock from trading on the Nasdaq Capital Market. It is expected that this plan would be effectuated in the fall of 2024, assuming the approval of Psychemedics' stockholders at the Company's 2024 Annual Meeting of Stockholders, among other things, as described below.
Psychemedics Unveils Inaugural Insights Report: Revealing Drug Trends Through Hair Testing
DALLAS, June 21, 2024 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ: PMD), a global leader in hair testing for drugs of abuse, proudly presents its inaugural Insights Report. This groundbreaking report offers a comprehensive analysis of drug trends in the workplace, drawing insights from a vast dataset of hair samples collected and analyzed in 2023.
Psychemedics Recognized as a Top 10 Employee Health Testing Services Provider
Dallas, TX, March 21, 2024 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ: PMD), a global leader in drug testing using hair analysis, is proud to announce its recognition as one of the Top 10 Employee Health Testing Services Providers for 2024 by ManageHR. This prestigious accolade highlights Psychemedics' commitment to excellence and innovation in the field of employee health testing.
Psychemedics Corporation Announces Relocation of Headquarters to Dallas, Texas
ACTON, Mass., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Psychemedics Corporation, a global leader in hair testing for drugs of abuse, proudly announces the relocation of its corporate headquarters from Acton, Massachusetts, to Dallas, Texas, while reaffirming its unwavering dedication to delivering exceptional service and maintaining the highest standards in hair drug testing.
Psychemedics Corporation Appoints Shannon Shoemaker as Chief Revenue Officer
ACTON, Mass., Sept. 21, 2023 (GLOBE NEWSWIRE) -- Psychemedics Corporation, the world's largest provider of hair testing for drugs of abuse, is pleased to announce the appointment of Shannon Shoemaker as its new Chief Revenue Officer. In this role, Shoemaker will be responsible for overseeing the company's revenue generation and growth strategies.
Psychemedics Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
ACTON, Mass., Aug. 18, 2023 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ: PMD), the world's largest provider of hair testing for drugs of abuse, announced the grant of inducement awards to its newly appointed President and Chief Executive Officer, Brian Hullinger, upon his entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4). Mr. Hullinger received an inducement grant option to purchase up to 300,000 shares of common stock. The inducement awards were granted on August 17, 2023, Mr. Hullinger's hire date as the Chief Executive Officer, and also the date on which he was elected to the Psychemedics Corporation Board of Directors. The options have a ten-year term and an exercise price of $4.65 per share, the closing price per share of Psychemedics Corporation common stock as reported by Nasdaq on August 17, 2023. The options were awarded in three tranches. Under the first tranche, option awards covering up to 100,000 shares vest over two years, with 50% of the original number of shares underlying the option vesting on the one-year anniversary of the date of grant and 50% on the two-year anniversary of the grant, subject to Mr. Hullinger's continued service with the Company through the applicable vesting dates. Under the second and third tranches, options to acquire 100,000 shares each were granted and each becomes exercisable in full only upon the attainment and continuation in effect for a specified period of time of a particular stock price on the Nasdaq Stock Market.
Psychemedics Corporation Reports Second Quarter 2023 Financial Results
ACTON, Mass., Aug. 11, 2023 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ: PMD), the world's largest provider of hair testing for drugs of abuse, today announced financial results for the second quarter ended June 30, 2023.
Small And Microcap Newsletter: DHT Holdings Financials Give It Time Until The Next Tanker Bull Market
In this week's newsletter, we look at a company in the middle of monetizing its major asset to see what is left after the deal closes. We also review a shipping company that has built a strong margin of safety.
Psychemedics Corporation Reports Stronger Second Quarter 2021 Financial Results
ACTON, Mass., Aug. 10, 2021 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ:PMD), the world's largest provider of hair testing for drugs of abuse, today announced financial results for the second quarter ended June 30, 2021.
Montana Advisors Writes Open Letter to Psychemedics
MIAMI--(BUSINESS WIRE)---- $PMD--Montana Advisors issues open letter to Psychemedics CEO (Nasdaq: PMD): Dear Kubacki: It was a pleasure speaking with you two months ago via Zoom. I appreciate the time you have given me to discuss Psychemedics Corp. (PMD or the “Company”). As you know, I continue to believe that PMD shares continue to trade at a significant discount to their intrinsic value. Montana has made recommendations on ways to unlock the value of the shares, including making your balance sheet wo
Psychemedics Corporation Reports Fourth Quarter and Full Year 2020 Financial Results
ACTON, Mass., March 23, 2021 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ:PMD), the world's largest provider of hair testing for drugs of abuse, today announced fourth quarter and full year financial results for the period ended December 31, 2020.
Robyn C. Davis Joins Psychemedics Board of Directors
ACTON, Mass., March 17, 2021 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ: PMD) announced that Robyn C. Davis was unanimously elected to serve on the Board of Directors of Psychemedics Corporation effective immediately. Ms. Davis will be filling the vacancy created by the untimely passing this past December of Clint Allen, a long- time and dedicated Psychemedics board member.
Similar Companies
Related Metrics
Explore detailed financial metrics and analysis for PMD.